Patent Application for Dichrostachys glomerata to Reduce Anxiety and Improve Mood

The USPTO has published a patent application (US20260083797A1) detailing methods and compositions using Dichrostachys glomerata to reduce anxiety, food cravings, and stress, and to improve mood, energy, and overall health in mammals. The application was filed on September 26, 2024.

US Patent Application for Heart Boosting Formulation

The USPTO has published a new patent application (US20260083806A1) for a heart boosting formulation. The application details a specific composition including L-carnitine, alpha-linolenic acid, citrulline, vitamin D3, lycopene, holy basil, cinnamon, and beetroot, along with related manufacturing methods. The filing date was September 16, 2025.

Antiviral Fungal Extracts Prevent Coronavirus Infections

The USPTO has published a patent application (US20260083788A1) detailing antiviral fungal extracts that may prevent coronavirus infections by interfering with the Spike protein. The application, filed by Mycotech Pharma AS, describes compositions derived from Agaricus blazei, Grifola frondosa, and Hericium erinaceus.

Patent Application: Reducing Food Intake Using Plants

The USPTO has published a new patent application (US20260083809A1) detailing methods and compositions using plants like Dichrostachys glomerata or Cissus quadrangularis to reduce food intake or appetite in mammals. The application was filed on September 26, 2024, and is expected to be published on March 26, 2026.

Patent Application: Reducing Visceral Fat Using Plants and Spices

The USPTO has published a new patent application (US20260083810A1) detailing methods and compositions for reducing visceral fat in mammals using plants and spices such as Dichrostachys glomerata or Cissus quadrangularis. The application was filed on September 26, 2024, and is scheduled for publication on March 26, 2026.

Patent Application: Reducing Blood Lipids Using Plants

The USPTO has published a patent application (US20260083811A1) detailing methods and compositions for reducing blood lipids using plants like Dichrostachys glomerata or Cissus quadrangularis. The application, filed on September 26, 2024, describes compositions aimed at increasing GLP-1 levels and reducing visceral fat, food intake, blood lipids, total cholesterol, and total glucose.

Patent Application: Reducing Fasting Blood Glucose Using Plants

The USPTO has published a new patent application detailing methods and compositions for reducing fasting blood glucose using plants like Dichrostachys glomerata or Cissus quadrangularis. The application, filed on September 26, 2024, describes oral dosage forms for health benefits including increased GLP-1 levels and reduced blood lipids.

Patent Application for Reducing DPP-4 Activity with Plants

The USPTO has published a new patent application (US20260083813A1) detailing methods and compositions using plants like Dichrostachys glomerata or Cissus quadrangularis to reduce DPP-4 activity or levels in mammals. The application was filed on September 26, 2024.

USPTO Patent Application for Dietary Supplement Formulation

The USPTO has published a patent application (US20260083814A1) for a dietary supplement formulation designed to alleviate sciatica pain and support nerve and musculoskeletal health. The application details a specific blend of natural ingredients and their purported benefits, filed on September 26, 2024.

Patent Application for Cancer Treatment Combination Therapies

The USPTO has published a new patent application (US20260083816A1) detailing methods for treating cancer using combination therapies. The application, filed by inventors Erlinda M. Gordon and Fredrick L. Hall, focuses on inhibiting cyclin proteins and targeting pathways that promote cyclin activity.

FDA Acknowledgment Letter to Ingram Planetarium

The Food and Drug Administration (FDA) has issued an acknowledgment letter to Ingram Planetarium regarding a submission. The letter, dated March 26, 2026, confirms receipt of documentation from the Center for Devices and Radiological Health (CDRH). No specific details about the submission's content or regulatory implications are provided.

FDA Variance Application from Axion Laser

The Food and Drug Administration (FDA) has posted a variance application from Axion Laser. This document is available for review on the FDA's regulations.gov portal.

FDA Variance Approval Letter to DePaul University

The FDA's Center for Devices and Radiological Health (CDRH) has issued a variance approval letter to DePaul University's Idea Realization Laboratory. This document signifies approval for a specific variance related to medical device development or testing.

FDA Completeness Assessment Correspondence

The Food and Drug Administration (FDA) has posted Completeness Assessment Correspondence related to drug applications. This notice indicates that documentation is available for review via the provided URL, though no specific documents are directly viewable or downloadable from the initial posting.

FDA Complaint Document - Closed for Comments

The Food and Drug Administration (FDA) has opened a public comment period for a new complaint document, identified by docket number FDA-2026-H-2944. The comment period is scheduled to close on March 26th.

FDA Complaint Document Details

The Food and Drug Administration (FDA) has posted details regarding a complaint document, with the information made available on March 26, 2026. The document is related to the Center for Tobacco Products (CTP) and is available for download.

FDA Variance Amendment from DePaul University Idea Realization Laboratory

The Food and Drug Administration (FDA) has posted a variance amendment submitted by DePaul University's Idea Realization Laboratory. The document is available for review on the Regs.gov platform, with an associated attachment from the Center for Devices and Radiological Health (CDRH).

FDA Variance Approval Letter

The Food and Drug Administration (FDA) has issued a variance approval letter to Laina Callow. The letter, originating from the Center for Devices and Radiological Health (CDRH), indicates a specific approval related to a medical device or process. A redacted version is available for public review.

FDA Variance Approval Letter to Dapper Rave, LLC

The Food and Drug Administration (FDA) has issued a variance approval letter to Dapper Rave, LLC, through its Center for Devices and Radiological Health (CDRH). This document signifies an approval for a specific variance requested by the company.

FDA Decision on Tradipitant New Drug Application Refusal

The Food and Drug Administration (FDA) has issued a final decision regarding the new drug application for Tradipitant. The agency has decided to refuse to approve the application, based on a proposal to do so. The specific details of the decision are confidential business information, but a redacted version is available.

FDA Acknowledgment Letter to Axion Laser

The Food and Drug Administration (FDA) has issued an acknowledgment letter from its Division of Management and Budget (DMB) to Axion Laser. This notice confirms receipt of a submission, though no specific details about the submission's content or purpose are provided in the available information.

FDA Variance Application from Ingram Planetarium

The Food and Drug Administration (FDA) has posted a variance application from Ingram Planetarium. The application is available for review on Regulations.gov, with the author listed as CDRH.

Citizen Petition Filed by Premier Research International LLC

Premier Research International LLC has filed a citizen petition with the Food and Drug Administration (FDA) regarding regulatory matters. The petition is available for public review and comment.

FDA Acknowledgment Letter to Laina Callow

The Food and Drug Administration (FDA) has issued an acknowledgment letter to Laina Callow regarding a submission. The document is a redacted version of an acknowledgment letter from the FDA's Division of Management and Budget (DMB) to Laina Callow, authored by CDRH.

FDA CDER Final Response Letter to Age Reversal Unity

The FDA's Center for Drug Evaluation and Research (CDER) has issued a final response letter to Age Reversal Unity regarding their submissions. The document is available through the Regs.gov portal.

FDA Acknowledgement Letter to Premier Research International, LLC

The Food and Drug Administration (FDA) has issued an acknowledgement letter to Premier Research International, LLC. This notice confirms receipt of a submission, though no specific details about the submission's content or regulatory implications are provided.

FDA Acknowledges Letter to DePaul University

The Food and Drug Administration (FDA) has acknowledged receipt of a letter from DePaul University's Idea Realization Laboratory. This notice serves as an acknowledgment of the correspondence, with no further regulatory action or guidance provided at this time.

FDA Variance Request from Laina Callow - Comment Period Closed

The Food and Drug Administration (FDA) has closed the comment period for a variance request submitted by Laina Callow. The application, authored by CDRH, was available for public comment on regulations.gov.

FDA Final Response Letter to Athyna Pharma LLC

The Food and Drug Administration (FDA) Center for Drug Evaluation and Research (CDER) has issued a final response letter to Athyna Pharma LLC. This document provides specific feedback and guidance related to the company's pharmaceutical development or regulatory submissions.

FDA CDRH Variance Approval Letter to Axion Laser

The FDA's Center for Devices and Radiological Health (CDRH) has issued a variance approval letter to Axion Laser. This document grants a specific variance, indicating an approved deviation from standard regulatory requirements for a particular product or process.

DePaul University Variance Application

The FDA has posted a variance application submitted by DePaul University's Idea Realization Laboratory. The document is available for review on the Regs.gov platform. No specific compliance actions or deadlines are indicated for other entities.

Cancer Treatment Using TTFields and Interferon Gamma Compositions

The USPTO has published a new patent application detailing compositions, systems, and methods for treating cancer using Tumor Treating Fields (TTFields) in combination with interferon gamma. The application, filed on September 18, 2025, outlines a method for reducing cancer cell viability and tumor volume.

Patent Application: Autism Symptom Treatment via Neurotensin Receptor Activation

The USPTO has published a new patent application (US20260083820A1) from the New York Institute of Technology for methods and formulations to treat autism symptoms by activating neurotensin receptor 1 (NTSR1) without causing significant lethargy. The application was filed on October 3, 2025.

Ocular Insulin Delivery Enhanced by Prostaglandin Analogues Patent Application

The USPTO has published a patent application (US20260083822A1) for a novel ocular insulin delivery system. The invention utilizes prostaglandin analogues to enhance insulin permeability across ocular tissues, offering a non-invasive alternative to injections for therapeutic effects.

Wound healing composition with amino acids and fish collagen

The USPTO has published a new patent application detailing a composition for promoting wound healing. The composition includes an amino acid mixture and fish collagen, with a method for its administration also described. This application was filed on September 20, 2024.

Patent Application for DNase Enzyme Therapy for Tumor Microenvironment Immunomodulation

The USPTO has published a patent application (US20260083827A1) filed by CLS THERAPEUTICS LIMITED for methods of immunomodulating the tumor microenvironment using DNase enzyme therapy. The application details methods involving the administration of DNase enzyme, alone or with other agents, to combat immunosuppressive tumor cell microenvironments.

Patent Application for Biodegradable Particles Delivering Therapeutic Agents

The USPTO has published a new patent application (US20260083830A1) for biodegradable polymeric particles designed for the extended, controlled release of positively charged therapeutic agents at neutral pH. The application details microparticles and nanoparticles comprising an uncapped polymer matrix and a net positively charged therapeutic agent.

USPTO Patent Application for WNT-Related Cancer Vaccines

The USPTO has published a patent application (US20260083831A1) filed by Geneos Therapeutics, Inc. The application details compositions and methods for treating WNT-related cancers using nucleic acid sequences encoding tumor-specific antigens, potentially in combination with checkpoint inhibitors.

Novel agent for Alzheimer's treatment using dynamin 1 peptide

The USPTO has published a new patent application (US20260083826A1) from the Okinawa Institute of Science and Technology School Corporation for a novel agent to treat Alzheimer's disease. The application describes a peptide corresponding to dynamin 1, potentially encapsulated in nanoparticles for improved brain delivery.

Patent Application: Vaccine for Bordetella pertussis using antigen peptides

The USPTO has published a patent application (US20260083833A1) for a vaccine against Bordetella pertussis using antigen peptides. The application details a method for preventing infection by targeting specific peptides processed and presented by CD4+ T cells. This relates to ongoing research and development in vaccine technology.

Immune Cells Target EpCAM for Tumor Treatment

The USPTO has published a patent application (US20260083843A1) from SUZHOU IMMUNOHEAD BIOTECHNOLOGY CO., LTD. The application details the use of immune cells that target EpCAM for the prevention or treatment of metastatic tumors expressing EpCAM.

Cellicure, Inc. Patent Application for Engineered Immune Cells

The USPTO has published a patent application (US20260083845A1) filed by Cellicure, Inc. on September 22, 2023. The application details engineered immune cells, specifically chimeric antigen receptors (CARs) for enhanced killing activities, primarily targeting cancer treatment.

USPTO Patent Application: Polynucleotides Targeting NR4A3

The USPTO has published a patent application (US20260083846A1) filed by Lyell Immunopharma, Inc. The application describes polynucleotides designed to target the NR4A3 gene and their potential use in treating diseases, including cancer. The patent is scheduled to be published on March 26, 2026.

Patent for Radiation Dose Enhancement and Tumor Delineation

The USPTO has published a new patent application (US20260083850A1) for compounds, compositions, and methods related to radiation dose enhancement and tumor delineation. The application, assigned to the University of Connecticut, focuses on using barium nanoparticles for improved radiation therapy and tumor identification.

Proteoglycan Mimetics for Wound Healing and Angiogenesis

The USPTO has published a new patent application, US20260083852A1, detailing proteoglycan mimetics for enhanced wound healing and angiogenesis. The application describes compounds designed to support tissue regeneration and promote vascular repair, potentially limiting systemic exposure to VEGF activity.

USPTO Patent for Therapeutic Compounds Treating Cancer

The USPTO has published patent application US20260085059A1 for therapeutic compounds and methods of use in treating cancer. The patent was assigned to Servier Pharmaceuticals LLC and lists Samuel V. Agresta et al. as inventors. The application was filed on May 7, 2025.

Chemical Compound with Triazine Group and Production Method

The USPTO has published a patent application (US20260085087A1) for a chemical compound comprising a triazine group and its production method. The application relates to novel nucleotides and oligonucleotides with modified phosphate groups, potentially useful in diagnostics, gene therapy, and treating bacterial and viral diseases, including COVID-19.

CAR T-cell therapy combined with BTK inhibitors for cancer

The USPTO has published a new patent application (US20260083848A1) detailing a combination therapy for cancer treatment. The application describes the use of CAR T-cell therapy with BTK inhibitors for treating hematological malignancies. This represents a new disclosure in the field of cancer therapeutics.

Modified T-Cells for Bladder Cancer Treatment Application

The USPTO has published a patent application (US20260083849A1) detailing a method for treating bladder cancer using modified immunoresponsive cells. The application was filed on September 7, 2023, and is related to therapeutic applications in oncology.

Antimicrobial Compositions Patent Application

The USPTO has published a patent application (US20260083126A1) for antimicrobial compositions containing organosulfur compounds. The application, filed on September 8, 2023, describes compounds useful for treating microbial infections and for cleaning, disinfecting, or agricultural use.